STATUTORY INSTRUMENTS

2019 No. 775

The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

PART 2

Amendment of Part 1 (General)

Amendment of regulation 3 (scope of Regulations: special provisions)

5.—(1) Regulation 3 is amended as follows.

(2) In paragraph (12)(d)—

(a) in paragraph (i) insert " UK " before "marketing authorisation";

[[F1](b) after paragraph (i) insert—

"(ia) the EU marketing authorisation,".**]**

(3) In paragraph (15)—

(a) in sub-paragraph (a) insert " UK " before "marketing authorisation"; and

[F2](b) . . . . . .

Textual Amendments

F1 Reg. 5(2)(b) substituted for reg. 5(2)(b)(c) (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, **Sch. 2 para. 2(a)**

F2 Reg. 5(3)(b) omitted (3.8.2021) by virtue of The Human Medicines (Amendment) (EU Exit) Regulations 2021 (S.I. 2021/834), regs. 1(2), **3**

Commencement Information

I1 Reg. 5 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, **Sch. 5 para. 1(1)**), see reg. 1

Changes to legislation:
There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 5.